Homepage
Author:
Palvella Therapeutics Inc.
Posted Date:
March 23, 2026
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services
Palvella Therapeutics Inc.
March 23, 2026
Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin
Palvella Therapeutics Inc.
March 16, 2026
Palvella Therapeutics Launches “BEYOND mLM” Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations
Palvella Therapeutics Inc.
March 10, 2026
Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
Palvella Therapeutics Inc.
March 2, 2026
Palvella Therapeutics Announces Pricing of Upsized Public Offering
Palvella Therapeutics Inc.
February 25, 2026
Palvella Therapeutics Announces Proposed Public Offering
Palvella Therapeutics Inc.
February 24, 2026
Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
Palvella Therapeutics Inc.
February 24, 2026
Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
Palvella Therapeutics Inc.
February 23, 2026
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis
Palvella Therapeutics Inc.
February 2, 2026
Prev
1
2
